Shanghai Henlius Biotech, Inc. (HKG: 2696)
Hong Kong
· Delayed Price · Currency is HKD 20.15
-0.10 (-0.49%)
Nov 15, 2024, 4:08 PM HKT
Shanghai Henlius Biotech Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2017 |
| Revenue | 5,641 | 5,395 | 3,215 | 1,682 | 587.59 | 90.93 | Upgrade
|
| Revenue Growth (YoY) | 27.45% | 67.82% | 91.07% | 186.34% | 546.20% | 1125.29% | Upgrade
|
| Cost of Revenue | 1,510 | 1,476 | 844.62 | 522.75 | 182.12 | 71.82 | Upgrade
|
| Gross Profit | 4,131 | 3,919 | 2,370 | 1,160 | 405.47 | 19.11 | Upgrade
|
| Selling, General & Admin | 2,252 | 2,138 | 1,403 | 800.87 | 436.29 | 220.52 | Upgrade
|
| Research & Development | 1,053 | 1,119 | 1,395 | 1,024 | 894.14 | 607.83 | Upgrade
|
| Operating Expenses | 3,335 | 3,287 | 2,999 | 1,825 | 1,330 | 828.35 | Upgrade
|
| Operating Income | 796.15 | 631.7 | -628.53 | -665.25 | -924.95 | -809.24 | Upgrade
|
| Interest Expense | -119.25 | -110.54 | -105.67 | -84.82 | -43.71 | -48.31 | Upgrade
|
| Interest & Investment Income | 15.74 | 8.15 | 3.57 | 2.69 | 7.4 | 16.06 | Upgrade
|
| Currency Exchange Gain (Loss) | -5.68 | -1.42 | 32.92 | - | - | -32.28 | Upgrade
|
| Other Non Operating Income (Expenses) | 34.39 | 41.69 | 202.97 | -209.36 | -32.29 | 3.24 | Upgrade
|
| EBT Excluding Unusual Items | 721.36 | 569.58 | -494.73 | -956.74 | -993.54 | -870.53 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | -199.15 | - | - | -5.3 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | - | 1.02 | Upgrade
|
| Pretax Income | 721.36 | 569.58 | -693.89 | -956.74 | -993.54 | -874.81 | Upgrade
|
| Income Tax Expense | 29.02 | 23.56 | 1.37 | 27.31 | - | 0.66 | Upgrade
|
| Earnings From Continuing Operations | 692.34 | 546.02 | -695.26 | -984.05 | -993.54 | -875.47 | Upgrade
|
| Net Income | 692.34 | 546.02 | -695.26 | -984.05 | -993.54 | -875.47 | Upgrade
|
| Net Income to Common | 692.34 | 546.02 | -695.26 | -984.05 | -993.54 | -875.47 | Upgrade
|
| Shares Outstanding (Basic) | 543 | 543 | 542 | 539 | 530 | 497 | Upgrade
|
| Shares Outstanding (Diluted) | 544 | 543 | 542 | 539 | 530 | 497 | Upgrade
|
| Shares Change (YoY) | 0.11% | 0.25% | 0.59% | 1.75% | 6.52% | 16.54% | Upgrade
|
| EPS (Basic) | 1.27 | 1.01 | -1.28 | -1.83 | -1.88 | -1.76 | Upgrade
|
| EPS (Diluted) | 1.27 | 1.00 | -1.28 | -1.83 | -1.88 | -1.76 | Upgrade
|
| Free Cash Flow | 629.26 | 574.25 | 396.65 | -370.04 | -1,167 | -732.07 | Upgrade
|
| Free Cash Flow Per Share | 1.16 | 1.06 | 0.73 | -0.69 | -2.20 | -1.47 | Upgrade
|
| Gross Margin | 73.23% | 72.64% | 73.73% | 68.93% | 69.01% | 21.01% | Upgrade
|
| Operating Margin | 14.11% | 11.71% | -19.55% | -39.54% | -157.42% | -889.97% | Upgrade
|
| Profit Margin | 12.27% | 10.12% | -21.63% | -58.49% | -169.09% | -962.80% | Upgrade
|
| Free Cash Flow Margin | 11.16% | 10.64% | 12.34% | -21.99% | -198.54% | -805.10% | Upgrade
|
| EBITDA | 1,086 | 911.33 | -419.93 | -518.3 | -831.47 | -756.03 | Upgrade
|
| EBITDA Margin | 19.26% | 16.89% | -13.06% | -30.81% | -141.51% | - | Upgrade
|
| D&A For EBITDA | 290.27 | 279.63 | 208.6 | 146.95 | 93.49 | 53.21 | Upgrade
|
| EBIT | 796.15 | 631.7 | -628.53 | -665.25 | -924.95 | -809.24 | Upgrade
|
| EBIT Margin | 14.11% | 11.71% | -19.55% | -39.54% | -157.42% | - | Upgrade
|
| Effective Tax Rate | 4.02% | 4.14% | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.